FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2900829083> ?p ?o ?g. }

• W2900829083 endingPage "1520" @default.
• W2900829083 startingPage "1513" @default.
• W2900829083 abstract "Statins lower low‐density lipoprotein cholesterol (LDL‐C) and improve clinical outcomes in patients with atherosclerotic cardiovascular disease (CVD). Patients with acute coronary syndromes (ACS) often do not achieve LDL‐C targets despite potent statin treatment, and have a particularly high risk of early recurrent events. Evolocumab, a proprotein convertase subtilisin/kexin type (PCSK9)‐inhibitor resulting in rapid, marked LDL‐C reduction, has been studied in hypercholesterolemic subjects without CVD and stabilized patients with CVD; the feasibility, safety, and efficacy of this treatment initiated in the acute phase of ACS remain unknown. We report the design of evolocumab for early reduction of LDL‐cholesterol levels in patients with ACS (EVOPACS), a phase‐3, multicenter, randomized, double‐blind, placebo‐controlled trial to assess the feasibility, safety, and LDL‐C‐lowering efficacy of evolocumab on top of atorvastatin 40 mg in patients with ACS. The primary endpoint is percent change in LDL‐C from baseline to 8 weeks. Secondary endpoints are adverse events and serious adverse events. Against a background of beneficial cardiovascular effects of statins beyond LDL‐C lowering and in view of preclinical evidence of similar effects of PCSK9 inhibition, the study will also address a variety of exploratory endpoints including the change in C‐reactive protein and other inflammatory biomarkers; platelet reactivity; and occurrence of contrast‐induced acute kidney injury and myocardial injury in patients undergoing cardiac catheterization. An intracoronary imaging sub‐study will investigate the change from baseline in the lipid core burden index in non‐culprit lesions, as assessed by serial near‐infrared spectroscopy. Recruitment began in January 2018 and enrollment of 308 patients is planned." @default.
• W2900829083 created "2018-11-29" @default.
• W2900829083 creator A5017583358 @default.
• W2900829083 creator A5040134218 @default.
• W2900829083 creator A5040563213 @default.
• W2900829083 creator A5051530432 @default.
• W2900829083 creator A5052418415 @default.
• W2900829083 creator A5053194091 @default.
• W2900829083 creator A5065988752 @default.
• W2900829083 creator A5066913399 @default.
• W2900829083 creator A5071787539 @default.
• W2900829083 creator A5081653127 @default.
• W2900829083 creator A5085573148 @default.
• W2900829083 creator A5086449617 @default.
• W2900829083 date "2018-11-26" @default.
• W2900829083 modified "2023-10-03" @default.
• W2900829083 title "Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial" @default.
• W2900829083 cites W140213998 @default.
• W2900829083 cites W1484156179 @default.
• W2900829083 cites W1520609538 @default.
• W2900829083 cites W1539625223 @default.
• W2900829083 cites W16027210 @default.
• W2900829083 cites W162053157 @default.
• W2900829083 cites W1888435097 @default.
• W2900829083 cites W188966887 @default.
• W2900829083 cites W1990018236 @default.
• W2900829083 cites W1996626325 @default.
• W2900829083 cites W2010033213 @default.
• W2900829083 cites W2021878270 @default.
• W2900829083 cites W2029684068 @default.
• W2900829083 cites W2056256068 @default.
• W2900829083 cites W2070396041 @default.
• W2900829083 cites W2080443045 @default.
• W2900829083 cites W2096079570 @default.
• W2900829083 cites W2102785524 @default.
• W2900829083 cites W2105397247 @default.
• W2900829083 cites W2107313543 @default.
• W2900829083 cites W2111099202 @default.
• W2900829083 cites W2118154631 @default.
• W2900829083 cites W2120631075 @default.
• W2900829083 cites W2127469535 @default.
• W2900829083 cites W2131110587 @default.
• W2900829083 cites W2150100875 @default.
• W2900829083 cites W2160152341 @default.
• W2900829083 cites W2160637851 @default.
• W2900829083 cites W2161089842 @default.
• W2900829083 cites W2194274372 @default.
• W2900829083 cites W2205413694 @default.
• W2900829083 cites W2261871796 @default.
• W2900829083 cites W2269530462 @default.
• W2900829083 cites W2305945749 @default.
• W2900829083 cites W2545046068 @default.
• W2900829083 cites W2596179513 @default.
• W2900829083 cites W2600369610 @default.
• W2900829083 cites W2766784925 @default.
• W2900829083 cites W2790051199 @default.
• W2900829083 cites W2790531075 @default.
• W2900829083 cites W4236531408 @default.
• W2900829083 cites W57851565 @default.
• W2900829083 doi "https://doi.org/10.1002/clc.23112" @default.
• W2900829083 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6490138" @default.
• W2900829083 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30421481" @default.
• W2900829083 hasPublicationYear "2018" @default.
• W2900829083 type Work @default.
• W2900829083 sameAs 2900829083 @default.
• W2900829083 citedByCount "19" @default.
• W2900829083 countsByYear W29008290832019 @default.
• W2900829083 countsByYear W29008290832020 @default.
• W2900829083 countsByYear W29008290832021 @default.
• W2900829083 countsByYear W29008290832022 @default.
• W2900829083 countsByYear W29008290832023 @default.
• W2900829083 crossrefType "journal-article" @default.
• W2900829083 hasAuthorship W2900829083A5017583358 @default.
• W2900829083 hasAuthorship W2900829083A5040134218 @default.
• W2900829083 hasAuthorship W2900829083A5040563213 @default.
• W2900829083 hasAuthorship W2900829083A5051530432 @default.
• W2900829083 hasAuthorship W2900829083A5052418415 @default.
• W2900829083 hasAuthorship W2900829083A5053194091 @default.
• W2900829083 hasAuthorship W2900829083A5065988752 @default.
• W2900829083 hasAuthorship W2900829083A5066913399 @default.
• W2900829083 hasAuthorship W2900829083A5071787539 @default.
• W2900829083 hasAuthorship W2900829083A5081653127 @default.
• W2900829083 hasAuthorship W2900829083A5085573148 @default.
• W2900829083 hasAuthorship W2900829083A5086449617 @default.
• W2900829083 hasBestOaLocation W29008290831 @default.
• W2900829083 hasConcept C126322002 @default.
• W2900829083 hasConcept C141341695 @default.
• W2900829083 hasConcept C142724271 @default.
• W2900829083 hasConcept C164705383 @default.
• W2900829083 hasConcept C168563851 @default.
• W2900829083 hasConcept C197934379 @default.
• W2900829083 hasConcept C203092338 @default.
• W2900829083 hasConcept C204787440 @default.
• W2900829083 hasConcept C27081682 @default.
• W2900829083 hasConcept C2776839432 @default.
• W2900829083 hasConcept C2777482532 @default.
• W2900829083 hasConcept C2778114629 @default.
• W2900829083 hasConcept C2778163477 @default.

• next